The US pharma hopes that the drug will be used in those patients ... have been withdrawn in bladdercancer as a result. Gilead said Trodelvy’s safety profile in the TROPHY study is consistent ...
The announcement comes shortly after Gilead faced pressure to open lenacapavir to a patent pool that would allow generics to be sold under license in those countries. The antiretroviral drug has ...
Results that may be inaccessible to you are currently showing.